Drug
AP Pa02
AP Pa02: highest development phase Phase 2, developed by Armata Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Armata Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| AP-PA02 NCT05616221 | Phase 2 | Non-cystic Fibrosis Bronchiectasis |
| AP-PA02 NCT04596319 | Phase 1/2 | Cystic Fibrosis |
Latest
No recent events.
Follow AP Pa02 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.